Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study

English version

Autoři: Elisé G. Kaboré ^aff001; Charles Guenancia ^aff002; Ines Vaz-Luis ^aff003; Antonio Di Meglio ^aff003; Barbara Pistilli ^aff003; Charles Coutant ^aff004; Paul Cottu ^aff005; Anne Lesur ^aff006; Thierry Petit ^aff007; Florence Dalenc ^aff008; Philippe Rouanet ^aff009; Antoine Arnaud ^aff010; Olivier Arsene ^aff011; Mahmoud Ibrahim ^aff012; Johanna Wassermann ^aff013; Geneviève Boileau-Jolimoy ^aff014; Anne-Laure Martin ^aff015; Jérôme Lemonnier ^aff015; Fabrice André ^aff003; Patrick Arveux ^aff001
Působiště autorů: “Health across Generations” Team, Inserm U1018, Centre for Research in Epidemiology and Population Health (CESP), Villejuif, France ^aff001; Cardiology Department, University Hospital Dijon Bourgogne, Dijon, France ^aff002; Institut Gustave Roussy, Villejuif, France ^aff003; Centre Georges-François Leclerc, Dijon, France ^aff004; Institut Curie, Paris, France ^aff005; Centre Alexis Vautrin, Vandoeuvre les Nancy, France ^aff006; Centre Paul Strauss, Strasbourg, France ^aff007; Institut Claudius Regaud, Toulouse, France ^aff008; Institut du Cancer de Montpellier, Montpellier, France ^aff009; Clinique Sainte Catherine, Avignon, France ^aff010; Centre Hospitalier de Blois, Blois, France ^aff011; Centre Hospitalier Régional d’Orléans, Orléans, France ^aff012; AP-HP Pitié-Salpêtrière, Paris, France ^aff013; Polyclinique du Parc Drevon, Dijon, France ^aff014; Unicancer, Paris, France ^aff015
Vyšlo v časopise: Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLoS Med 16(12): e32767. doi:10.1371/journal.pmed.1002989
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pmed.1002989

Souhrn

Background

In patients treated with cardiotoxic chemotherapies, the presence of cardiovascular risk factors and previous cardiac disease have been strongly correlated to the onset of cardiotoxicity. The influence of overweight and obesity as risk factors in the development of treatment-related cardiotoxicity in breast cancer (BC) was recently suggested. However, due to meta-analysis design, it was not possible to take into account associated cardiac risk factors or other classic risk factors for anthracycline (antineoplastic antibiotic) and trastuzumab (monoclonal antibody) cardiotoxicity.

Methods and findings

Using prospective data collected from 2012–2014 in the French national multicenter prospective CANTO (CANcer TOxicities) study of 26 French cancer centers, we aimed to examine the association of body mass index (BMI) and cardiotoxicity (defined as a reduction in left ventricular ejection fraction [LVEF] > 10 percentage points from baseline to LVEF < 50%). In total, 929 patients with stage I–III BC (mean age 52 ± 11 years, mean BMI 25.6 ± 5.1 kg/m², 42% with 1 or more cardiovascular risk factors) treated with anthracycline (86% epirubicin, 7% doxorubicin) and/or trastuzumab (36%), with LVEF measurement at baseline and at least 1 assessment post-chemotherapy were eligible in this interim analysis. We analyzed associations between BMI and cardiotoxicity using multivariate logistic regression. At baseline, nearly 50% of the study population was overweight or obese. During a mean follow-up of 22 ± 2 months following treatment completion, cardiotoxicity occurred in 29 patients (3.2%). The obese group was more prone to cardiotoxicity than the normal-weight group (9/171 versus 8/466; p = 0.01). In multivariate analysis, obesity (odds ratio [OR] 3.02; 95% CI 1.10–8.25; p = 0.03) and administration of trastuzumab (OR 12.12; 95% CI 3.6–40.4; p < 0.001) were independently associated with cardiotoxicity. Selection bias and relatively short follow-up are potential limitations of this national multicenter observational cohort.

Conclusions

In BC patients, obesity appears to be associated with an important increase in risk-related cardiotoxicity (CANTO, ClinicalTrials.gov registry ID: NCT01993498).

Trial registration

ClinicalTrials.gov NCT01993498.

Klíčová slova:

Body Mass Index – Breast cancer – Cancer chemotherapy – Cancer risk factors – Cancer treatment – Hypertension – Obesity

Zdroje

1. Rosa GM, Gigli L, Tagliasacchi MI, Di Iorio C, Carbone F, Nencioni A, et al. Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest. 2016;46:264–84. doi: 10.1111/eci.12589 26728634

2. Volkova M, Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7:214–20. doi: 10.2174/157340311799960645 22758622

3. Santoni M, Guerra F, Conti A, Lucarelli A, Rinaldi S, Belvederesi L, et al. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. Cancer Treat Rev. 2017;59:123–31. doi: 10.1016/j.ctrv.2017.07.006 28818671

4. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–14. doi: 10.1161/CIRCULATIONAHA.115.020406 26976915

5. Majed B, Moreau T, Asselain B, Curie Institute Breast Cancer Group. Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points. Breast Cancer Res Treat. 2009;115:193–203. doi: 10.1007/s10549-008-0065-7 18546073

6. Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008;111:329–42. doi: 10.1007/s10549-007-9785-3 17939036

7. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–91. doi: 10.1038/nrc1408 15286738

8. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78. doi: 10.1016/S0140-6736(08)60269-X 18280327

9. Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol. 2016;34:3157–65. doi: 10.1200/JCO.2016.67.4846 27458291

10. Mitra MS, Donthamsetty S, White B, Mehendale HM. High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity. Toxicol Appl Pharmacol. 2008;231:413–22. doi: 10.1016/j.taap.2008.05.006 18674790

11. Guenancia C, Hachet O, Aboutabl M, Li N, Rigal E, Cottin Y, et al. Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity. Cancer Chemother Pharmacol. 2016;77:777–85. doi: 10.1007/s00280-016-2995-9 26914236

12. Vaz-Luis I, Cottu P, Mesleard C, Martin AL, Dumas A, Dauchy S, et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open. 2019;4:e000562. doi: 10.1136/esmoopen-2019-000562 31555487

13. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. doi: 10.1093/eurheartj/ehw211 27567406

14. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452. 8594834

15. Armenian S, Lacchetti C, Barac A, Carver J, Constine L, Denduluri N. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893–911. doi: 10.1200/JCO.2016.70.5400 27918725

16. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther. 2017;31:63–75. doi: 10.1007/s10557-016-6711-0 28185035

17. Colombo A, Sandri MT, Salvatici M, Cipolla CM, Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med. 2014;16:313. doi: 10.1007/s11936-014-0313-6 24771223

18. Kongbundansuk S, Hundley WG. Noninvasive imaging of cardiovascular injury related to the treatment of cancer. JACC Cardiovasc Imaging. 2014;7:824–38. doi: 10.1016/j.jcmg.2014.06.007 25124015

19. Agmon Nardi I, Iakobishvili Z. Cardiovascular risk in cancer survivors. Curr Treat Options Cardiovasc Med. 2018;20:47. doi: 10.1007/s11936-018-0645-8 29705862

20. Linschoten M, Teske AJ, Cramer MJ, van der Wall E, Asselbergs FW. Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ Genom Precis Med. 2018;11:e001753. doi: 10.1161/CIRCGEN.117.001753 29557343

21. Kenchaiah S, Sesso HD, Gaziano JM. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation. 2009;119:44–52. doi: 10.1161/CIRCULATIONAHA.108.807289 19103991

22. Kenchaiah S, Chesebro JH. The epidemiologic association between obesity and heart failure. Am Coll Cardiol Ext Learn. 2017;49:4–6. 29527015

23. Hirayama A, Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Association of obesity with severity of heart failure exacerbation: a population-based study. J Am Heart Assoc. 2018;7:e008243. doi: 10.1161/JAHA.117.008243 29545263

24. Guglin M, Munster P, Fink A, Krischer J. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: a rationale and design of a randomized clinical trial. Am Heart J. 2017;188:87–92. doi: 10.1016/j.ahj.2017.03.010 28577685

25. Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107. doi: 10.1016/j.metabol.2018.10.011 30399375

26. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97. doi: 10.1038/nri2921 21252989